Target Name: HLA class II histocompatibility Antigen DO (HLA-DO)
NCBI ID: P16379
Review Report on HLA class II histocompatibility Antigen DO (HLA-DO) Target / Biomarker Content of Review Report on HLA class II histocompatibility Antigen DO (HLA-DO) Target / Biomarker
HLA class II histocompatibility Antigen DO (HLA-DO)
Other Name(s): Major histocompatibility complex, class II, DO | HLA-DO

HLA-DO: A Protein in The Immune System

The major histocompatibility complex (MHC) is a crucial part of the immune system that helps our bodies fight off infection and disease. It is a complex protein molecule that is present in all cells of the body, and it is responsible for presenting antigens from the body's immune system to the immune system's T-cells. HLA class II histocompatibility antigen DO (HLA-DO) is a type of antigen that is recognized by T-cells of the immune system.

HLA-DO is a 26-kDa protein that is located in the MHC class II region. It is one of the proteins that are present in the major histocompatibility complex (MHC) and is responsible for presenting antigens from the body's immune system to T-cells. It is found in most tissues and cells of the body, including the skin, hair, nails, teeth, and the gut.

HLA-DO is a type of antigen that is recognized by T-cells of the immune system. It is part of the major histocompatibility complex (MHC), which is a crucial part of the immune system that helps our bodies fight off infection and disease. The MHC is a complex protein molecule that is present in all cells of the body, and it is responsible for presenting antigens from the body's immune system to the immune system's T-cells.

HLA-DO is a type of protein that is found in most tissues and cells of the body. It is a crucial part of the immune system and helps our bodies fight off infection and disease. The MHC is a complex protein molecule that is present in all cells of the body and is responsible for presenting antigens from the body's immune system to the immune system's T-cells.

HLA-DO is a protein that is found in most tissues and cells of the body. It is a crucial part of the immune system and helps our bodies fight off infection and disease. The MHC is a complex protein molecule that is present in all cells of the body and is responsible for presenting antigens from the body's immune system to the immune system's T-cells.

HLA-DO is a protein that is found in most tissues and cells of the body. It is a crucial part of the immune system and helps our bodies fight off infection and disease. The MHC is a complex protein molecule that is present in all cells of the body and is responsible for presenting antigens from the body's immune system to the immune system's T-cells.

In conclusion, HLA-DO is a protein that is found in most tissues and cells of the body. It is a crucial part of the immune system and helps our bodies fight off infection and disease. The MHC is a complex protein molecule that is present in all cells of the body and is responsible for presenting antigens from the body's immune system to the immune system's T-cells. HLA-DO may be a drug target or biomarker, and research is ongoing to determine its role in the immune system and its potential as a therapeutic target.

Protein Name: HLA Class II Histocompatibility Antigen DO (HLA-DO)

The "HLA class II histocompatibility Antigen DO (HLA-DO) Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HLA class II histocompatibility Antigen DO (HLA-DO) comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

HLA class II histocompatibility antigen DP (HLA-DP) | HLA Class II Histocompatibility Antigen DQ8 | HLA class II histocompatibility antigen DR (HLA-DR) | HLA Class II Histocompatibility Antigen, DQ (HLA-DQ) | HLA class II histocompatibility antigen, DRB1-7 beta chain, transcript variant X1 | HLA complex group 16 (non-protein coding), transcript variant X2 | HLA complex group 8 | HLA-A | HLA-B | HLA-C | HLA-DMA | HLA-DMB | HLA-DOA | HLA-DOB | HLA-DPA1 | HLA-DPA2 | HLA-DPA3 | HLA-DPB1 | HLA-DPB2 | HLA-DQA1 | HLA-DQA2 | HLA-DQB1 | HLA-DQB1-AS1 | HLA-DQB2 | HLA-DRA | HLA-DRB1 | HLA-DRB2 | HLA-DRB3 | HLA-DRB4 | HLA-DRB5 | HLA-DRB6 | HLA-DRB7 | HLA-DRB8 | HLA-DRB9 | HLA-E | HLA-F | HLA-F-AS1 | HLA-G | HLA-H | HLA-J | HLA-K | HLA-L | HLA-N | HLA-P | HLA-U | HLA-V | HLA-W | HLCS | HLF | HLTF | HLX | HM13 | HMBOX1 | HMBS | HMCES | HMCN1 | HMCN2 | HMG20A | HMG20B | HMGA1 | HMGA1P2 | HMGA1P4 | HMGA1P7 | HMGA1P8 | HMGA2 | HMGA2-AS1 | HMGB1 | HMGB1P1 | HMGB1P10 | HMGB1P19 | HMGB1P37 | HMGB1P38 | HMGB1P46 | HMGB1P5 | HMGB1P6 | HMGB2 | HMGB2P1 | HMGB3 | HMGB3P1 | HMGB3P14 | HMGB3P15 | HMGB3P19 | HMGB3P2 | HMGB3P22 | HMGB3P24 | HMGB3P27 | HMGB3P30 | HMGB3P6 | HMGB4 | HMGCL | HMGCLL1 | HMGCR | HMGCS1 | HMGCS2 | HMGN1 | HMGN1P16 | HMGN1P30 | HMGN1P37 | HMGN1P8 | HMGN2